| Identification | Back Directory | [Name]
Diquafosol | [CAS]
59985-21-6 | [Synonyms]
Up4U
Kpy 998
Diquafosol
Unii-7828vc80fj
Diquafosol [inn]
Diquafosol [inn:ban]
Diquafosol USP/EP/BP
5'-ester with uridine
Diquafosol Sodium Salt
Diquafosol intermediate
(2E,4Z,7Z)-trideca-2,4,7-trienal
P1,P4-Diuridine 5'-Tetraphosphate
Uridine 5'-(pentahydrogen tetraphosphate)
P(1),P(4)-bis(uridin-5'-yl) tetraphosphate
p1,p4-Bis(5'-uridyl) tetrahydrogen tetraphosphate
Uridine5'-(pentahydrogen tetraphosphate), P'''®
Uridine 5'-(Pentahydrogen Tetraphosphate), P'''→5'-Ester with Uridine
[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-phosphinic acid
[[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosph | [Molecular Formula]
C18H26N4O23P4 | [MDL Number]
MFCD09837994 | [MOL File]
59985-21-6.mol | [Molecular Weight]
790.31 |
| Chemical Properties | Back Directory | [density ]
2.044±0.06 g/cm3(Predicted) | [solubility ]
Water (Slightly) | [form ]
Solid | [pka]
0.40±0.50(Predicted) | [color ]
White to Pale Beige | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
Diquafosol is a dinucleoside derivative of uridine that acts as a selective P2Y2 receptor agonist. Diquafosol is used as a therapeutic agent in the treatment of dry eye syndrome. | [Definition]
ChEBI: A pyrimidine ribonucleoside 5'-tetraphosphate compound having 5'-uridinyl residues at the P1- and P4-positions. | [in vivo]
Diquafosol (ophthalmic solution 3%; eyedrop, four times daily for 28 days) reduces intracellular ROS levels, apoptosis, and inflammation in rat[1]. | Animal Model: | 6 weeks, 160-180 g Wistar female rats (dry eye model)[1] | | Dosage: | ophthalmic solution 3% | | Administration: | eyedrop, four times daily (8, 12 AM; 4, 8 PM) for 28 days | | Result: | Increased the expression of phospho-Erk1/2, phospho-Akt, and phospho-p90RSK, inhibits apoptosis, decreased the IL-1β, TNF-α expression. |
| [IC 50]
P2Y2 Receptor |
|
|